tj003234
mAbexperimentalCOVID-19
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Mar 18, 2019 (NCT03794180)
Timeline
2010s
- Jan 1, 2019
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Granulocyte-macrophage colony-stimulating factor antagonist
CSF2 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650518 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07208058 | Phase 3 | Oct 1, 2025 | — |
| NCT07034209 | Phase 2 | Apr 7, 2023 | — |
| NCT04457856 | Phase 1 | Aug 6, 2020 | I-Mab Biopharma |
| NCT04341116 | Phase 1/Phase 2 (Phase 2) | Apr 11, 2020 | I-Mab Biopharma |
| NCT03794180 | Phase 1 | Mar 18, 2019 | I-Mab Biopharma |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| I-Mab Biopharma | For profit | 3 | 3 | 2 | 2019 |
1 organizations
Page 1 / 1